Multicenter, Open-Label, Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis or Compensated Cirrhosis.

Trial Profile

Multicenter, Open-Label, Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis or Compensated Cirrhosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C; HIV-1 infections; HIV-2 infections
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 25 Sep 2015 Results published in the Journal of Infection.
    • 04 Sep 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 05 Feb 2014 Planned End Date changed from 1 Sep 2014 to 1 Aug 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top